Rising Biosciences, Inc. Propels Q2 Revenues to Nearly $350,000 Due to Exceptional Growth of Oxi Thyme Division
9:00 AM ET 7/17/20 | Dow Jones
SANDUSKY, OH / ACCESSWIRE / July 17, 2020 / Rising Biosciences, Inc. (OTC PINK:RBII) CEO Arthur Hall announced significant revenue growth to nearly $350,000 in Q2 as sales and reception of the company's Oxi Thyme have escalated dramatically.
"The activity over the last three months has been incredible", said Hall. "We have already outgrown our original bottling plant and are in the process of building a second bottling facility in South Florida.
Currently, we are operating in 14 states, servicing 74 regions from Anchorage, AK to Key West, FL, with more going on line each week."
Oxi Thyme has introduced a proprietary system designed to sanitize and disinfect varying facilities in the current challenging environment, quickly and cost effectively. Utilizing a proprietary formulated EPA registered Hydrogen Peroxide disinfectant, developed with a surfactant, or surface active agent, Oxi Thyme improves efficiency by lowering surface tension. The addition of a surfactant and the use of an atomizing ULV (ultra low volume) or HVLP (high volume, low pressure) fogging system allows the droplets of disinfectant to disperse more evenly and cover larger surface areas, creating a no touch solution to sanitizing large areas quickly and efficiently leaving no toxic residue.
"We are living in challenging times", Hall added, "and experiencing a dramatic climate of change with this Covid-19 pandemic. People are struggling to establish what our new normal will be with respect to safety standards. Oxi Thyme has heard the call and we are here to help!"
